Skip Nav Destination
How I treat hemophagocytic lymphohistiocytosis
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia
The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia
A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria
Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies
Issue Archive
October 13 2011
In this Issue
Table of Contents
Inside Blood
Plenary Paper
Review Article
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
Werner Kempf,Katrin Pfaltz,Maarten H. Vermeer,Antonio Cozzio,Pablo L. Ortiz-Romero,Martine Bagot,Elise Olsen,Youn H. Kim,Reinhard Dummer,Nicola Pimpinelli,Sean Whittaker,Emmilia Hodak,Lorenzo Cerroni,Emilio Berti,Steve Horwitz,H. Miles Prince,Joan Guitart,Teresa Estrach,José A. Sanches,Madeleine Duvic,Annamari Ranki,Brigitte Dreno,Sonja Ostheeren-Michaelis,Robert Knobler,Gary Wood,Rein Willemze
Evidence-Based Focused Review
How I treat
How I treat hemophagocytic lymphohistiocytosis
Clinical Trials & Observations
Clinical Trials and Observations
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
Clinical Trials & Observations
Ivana N. M. Micallef,Matthew J. Maurer,Gregory A. Wiseman,Daniel A. Nikcevich,Paul J. Kurtin,Michael W. Cannon,Domingo G. Perez,Gamini S. Soori,Brian K. Link,Thomas M. Habermann,Thomas E. Witzig
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target
Clinical Trials & Observations
Dale J. Christensen,Youwei Chen,Jessica Oddo,Karen M. Matta,Jessica Neil,Evan D. Davis,Alicia D. Volkheimer,Mark C. Lanasa,Daphne R. Friedman,Barbara K. Goodman,Jon P. Gockerman,Louis F. Diehl,Carlos M. de Castro,Joseph O. Moore,Michael P. Vitek,J. Brice Weinberg
Hematopoiesis and Stem Cells
Immunobiology
Lymphoid Neoplasia
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia
Clinical Trials & Observations
Marco Montillo,Alessandra Tedeschi,Valeria Belsito Petrizzi,Francesca Ricci,Monica Crugnola,Mauro Spriano,Pierangelo Spedini,Fiorella Ilariucci,Lilj Uziel,Immacolata Attolico,Eleonora Vismara,Angelo De Blasio,Alfonso Zaccaria,Enrica Morra
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma
Richard J. Jones,Veerabhadran Baladandayuthapani,Sattva Neelapu,Luis E. Fayad,Jorge E. Romaguera,Michael Wang,Rakesh Sharma,Dajun Yang,Robert Z. Orlowski
A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies
Karl-Heinz Heider,Kerstin Kiefer,Thorsten Zenz,Matthias Volden,Stephan Stilgenbauer,Elinborg Ostermann,Anke Baum,Herbert Lamche,Zaruhi Küpcü,Alexander Jacobi,Steffen Müller,Ulrich Hirt,Günther R. Adolf,Eric Borges
The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia
Brief Report
Alejandro Gutierrez,Alex Kentsis,Takaomi Sanda,Linda Holmfeldt,Shann-Ching Chen,Jianhua Zhang,Alexei Protopopov,Lynda Chin,Suzanne E. Dahlberg,Donna S. Neuberg,Lewis B. Silverman,Stuart S. Winter,Stephen P. Hunger,Stephen E. Sallan,Shan Zha,Frederick W. Alt,James R. Downing,Charles G. Mullighan,A. Thomas Look
Myeloid Neoplasia
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia
Clinical Trials & Observations
Sebastian Schwind,Guido Marcucci,Jessica Kohlschmidt,Michael D. Radmacher,Krzysztof Mrózek,Kati Maharry,Heiko Becker,Klaus H. Metzeler,Susan P. Whitman,Yue-Zhong Wu,Bayard L. Powell,Maria R. Baer,Jonathan E. Kolitz,Andrew J. Carroll,Richard A. Larson,Michael A. Caligiuri,Clara D. Bloomfield
Phagocytes, Granulocytes, and Myelopoiesis
Platelets and Thrombopoiesis
Red Cells, Iron, and Erythropoiesis
Thrombosis and Hemostasis
Transplantation
A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
Clinical Trials & Observations
George L. Chen,Sally Arai,Mary E. D. Flowers,Joanne M. Otani,Jingxin Qiu,Ethan C. Cheng,Alex McMillan,Laura J. Johnston,Judith A. Shizuru,David B. Miklos
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria
Clinical Trials & Observations
Sally Arai,Madan Jagasia,Barry Storer,Xiaoyu Chai,Joseph Pidala,Corey Cutler,Mukta Arora,Daniel J. Weisdorf,Mary E. D. Flowers,Paul J. Martin,Jeanne Palmer,David Jacobsohn,Steven Z. Pavletic,Georgia B. Vogelsang,Stephanie J. Lee
Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease
Clinical Trials & Observations
Kathryn J. Martires,Kristin Baird,Seth M. Steinberg,Lana Grkovic,Galen O. Joe,Kirsten M. Williams,Sandra A. Mitchell,Manuel Datiles,Fran T. Hakim,Steven Z. Pavletic,Edward W. Cowen
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies
Clinical Trials & Observations
John Magenau,Hiromi Tobai,Attaphol Pawarode,Thomas Braun,Edward Peres,Pavan Reddy,Carrie Kitko,Sung Choi,Gregory Yanik,David Frame,Andrew Harris,Harry Erba,Lisa Kujawski,Kojo Elenitoba-Johnson,Jennifer Sanks,Dawn Jones,Sophie Paczesny,James Ferrara,John Levine,Shin Mineishi
Vascular Biology
-
Cover Image
Cover Image
![issue cover]()
This immunohistologic micrograph (magnification 400) demonstrates expression of CD30 (red) by the anaplastic tumor cells in lymphomatoid papulosis. See the article by Kempf et al on page 4024.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement
Email alerts
Advertisement
